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Association between Symptoms of Irritable Bowel Syndrome and 
Methane and Hydrogen on Lactulose Breath Test
Whether hydrogen and methane gas produced during lactulose breath test (LBT) are 
associated with symptoms of irritable bowel syndrome (IBS) is not determined. We aimed 
to investigate whether hydrogen and methane on LBT are associated with IBS symptoms. 
Sixty-eight IBS patients meeting the Rome III criteria for IBS, and 55 healthy controls, 
underwent LBT. The IBS subjects recorded their customary gastrointestinal symptoms on a 
questionnaire using visual analogue scales. LBT positivity was defined to be above 20 ppm 
rise of hydrogen or 10 ppm rise of methane within 90 min. Gas amounts produced during 
LBT were determined by calculating area under the curve of hydrogen and methane 
excretion. Symptom severity scores were not different between the LBT (+) IBS and LBT (-) 
IBS subjects and also between methane producers and non-methane producers. Gas 
amounts produced during LBT were not associated with IBS symptoms, except a weak 
correlation between total gas amounts and a few IBS symptoms such as bloating 
(r = 0.324, P = 0.039), flatulence (r = 0.314, P = 0.046) and abdominal pain (r = 0.364, 
P = 0.018) only in LBT (+) IBS. In conclusion, hydrogen and methane gas on LBT are not 
useful for predicting the customary symptoms and subtypes of IBS. 
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INTRODUCTION
Irritable bowel syndrome (IBS) is a functional gastrointestinal 
(GI) disorder characterized by bowel habit changes and ab-
dominal pain or discomfort relieved by defecation (1). Patients 
with IBS complain of diverse GI symptoms such as diarrhea, 
constipation, abdominal pain, bloating, urgency, and flatu-
lence. As there is no specific disease marker for IBS, it is diag-
nosed totally according to the standardized diagnostic criteria 
based on symptoms, the Rome criteria. Furthermore, its patho-
physiology is multifactorial: visceral hypersensitivity, intestinal 
dysmotility, abnormal brain-gut axis, genetic factors and al-
tered intestinal microbiota including small intestinal bacterial 
overgrowth (SIBO) (2). 
 Recently, SIBO has been advocated as a pathogenetic factor 
of IBS. It is defined as the presence of abnormally high num-
bers of bacteria or the growth of colon-type bacteria in the small 
intestine. Its predisposing factors include conditions with peri-
staltic impairment of small bowel or anatomical defects caus-
ing intestinal stasis. For the diagnosis of SIBO, invasive or non-
invasive test can be used. Lactulose breath test (LBT) is one of 
the non-invasive tests and can detect hydrogen and methane 
gas produced by bacterial fermentation of unabsorbed intesti-
nal lactulose and excreted in the breath. Studies using LBT re-
ported that IBS patients have SIBO more frequently than healthy 
controls (HC), and administration of antibiotics improved IBS 
symptoms together with eradication of SIBO and normaliza-
tion of breath test results (3, 4). However, LBT is not standard-
ized as study results are different according to the diagnostic 
criteria applied to the study (5) and therefore, SIBO as a cause 
of IBS still remains a matter of debate. 
 Despite multifactorial pathophysiology including SIBO, gas-
like symptoms including bloating are reported to be present in 
over 90% of IBS patients (6). Bloating could be explained by ex-
cessive amounts of intestinal gas. Intestinal gas is composed of 
predominantly N2 and O2 and includes variable concentrations 
of CO2, hydrogen and methane. Hydrogen is derived only from 
bacterial metabolism in the intestine. Excessive amount of hy-
drogen could be produced by fermentation of unabsorbed car-
bohydrates by the increased numbers of bacteria in the small 
and large intestines. It was demonstrated that maximal rate of 
hydrogen production and excretion was higher in IBS patients 
than controls and gas-like symptoms was improved by exclu-
sion diet of gas-forming foods (7). Methane is produced through 
consumption of hydrogen by methane-producing bacteria, me-
thanogens. Methane production in the intestine has recently 
reported to be associated with constipation. A direct inhibitory 
effect of the gas on intestinal transit has been suggested, based 
on in vivo and in vitro experiments (8), and reduction of post-
prandial serotonin levels has been suggested as a mediating 
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mechanism (9). Measurement of exhaled methane has even 
been advocated as a diagnostic test for IBS-C (10). However, 
methanogens in IBS patients was reported to be significantly 
lower than healthy controls in a study comparing 345 IBS sub-
jects with 254 matched healthy controls (11). 
 Therefore, it remains to be determined whether hydrogen or 
methane gas on LBT is associated with IBS symptoms and whe-
ther excessive amounts of hydrogen and methane produced 
during LBT are responsible for IBS symptoms including bloat-
ing. We aimed to investigate whether methane or hydrogen is 
associated with IBS subtypes and whether the amounts of hy-
drogen and methane gas correlates with customary GI symp-
toms in IBS patients. Therefore, we compared diverse IBS symp-
toms with LBT positivity for hydrogen and methane in IBS pa-
tients. We also compared the gas amounts of hydrogen and me-
thane calculated by AUC on LBT with symptom severity scores 
of IBS.
MATERIALS AND METHODS
Study subjects
Subjects with IBS were recruited from our gastroenterology 
outpatient unit and through advertisements from October 2006 
to October 2007. All IBS patients fulfilled the Rome III criteria 
for IBS (1). Exclusion criteria included conditions such as previ-
ous bowel resection, bowel adhesion, narcotics use, connective 
tissue diseases, diabetes, thyroid diseases, inflammatory bowel 
diseases or any organic GI diseases. Subjects with probiotics, 
antidepressants, or antibiotics use for the past three months 
were excluded. Of 75 IBS subjects recruited at first, we excluded 
2 patients with probiotics users, 3 patients with antibiotics, one 
patient with fibromyalgia and one with thyroid disease, and 
thus 68 IBS subjects participated in the study. Also through pa-
per advertisements in our hospital, we selected 55 healthy con-
trols (HCs) after interviewing them to confirm that they had no 
GI symptoms or illnesses. 
 The sample size was determined using a statistical power of 
80% and a type 1 error of 0.05. The number of IBS patients was 
determined by using the formula to calculate sample size in 
quantitative data in two groups based on the previous study to 
compare symptom severities of IBS (12), and the number of 
healthy controls was determined for the total enrollments to be 
over one hundred to follow a normal distribution. 
Study design
All subjects came to the laboratory at our gastroenterology unit 
after an overnight fast. Before LBT, subjects were asked to fill 
out a symptom questionnaire for evaluating the severity of their 
lower GI symptoms such as abdominal pain, diarrhea, consti-
pation, tenesmus, bloating, urgency, and flatulence, on a visual 
analogue scale ranging from 0 to 20, with 20 representing the 
extreme symptoms. The questionnaire was modified from the 
previous studies (13, 14). 
Lactulose breath test
All subjects were asked to have carbohydrate-restricted diets 
one day before the test to minimize their basal hydrogen excre-
tion. Smoking and physical exercises were not allowed 2 h prior 
to and during the test. Breath testing started after mouth wash-
ing with 20 mL of 1% chlorhexidine solution. After an initial 
baseline breath sample was collected, subjects ingested 15 mL 
of syrup containing 10 g lactulose (Duphalac®, Choong Wae 
Pharma Corporation, Seoul, Korea) with 200 mL of water. End-
alveolar breath samples were obtained at 15 min intervals for 
180 min with an Alveosampler (Quintron Instrument Co. Mil-
waukee, WI, USA). All breath samples were immediately ana-
lyzed to measure hydrogen and methane concentration in parts 
per million (ppm) using a QuinTron model SC gas chromato-
graph (QuinTron Instrument Co. Milwaukee, WI, USA). The 
measurements were plotted as a graph and interpreted (Fig. 1). 
LBT results were considered positive when breath hydrogen 
concentration rose over 20 ppm or methane over 10 ppm with-
in 90 min (9, 15, 16). As for methane, subjects who excrete more 
than 1 ppm of methane during LBT were defined as methane 
producers, while those who excrete less than 1 ppm of methane 
as non-methane producers (10-12, 17). Cumulative hydrogen 
or methane production was quantified from the graph by cal-
culating the area under the curve (AUC) of hydrogen or meth-
ane concentration over time (18). Total amounts of hydrogen 
plus methane were also calculated by adding the AUC of hydro-
gen to that of methane. 
Statistical analysis
For each of the three gas patterns (hydrogen, methane and total 
gas patterns) obtained in the LBT, the correlation with IBS symp-
toms was analyzed by the chi-square test or Fisher’s exact test. 
Symptom severity scores and gas amounts in the IBS patients 
and HCs were compared by t-test. The relationship between 
Fig. 1. Schematic drawing of lactulose breath tests indicating positivity for hydrogen. 
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AUCs of gas and symptom severity scores was analyzed by Pear-
son’s correlation test. Data are reported as mean ± standard 
deviation and P values less than 0.05 are considered significant. 
Statistical analysis for gender adjustment was performed by 
SAS (ver 9.2).
Ethics statement
The study was approved by the institutional review board of the 
Hanyang University Hospital (IRB No. 2006-08-001). Written 
informed consent was obtained from all subjects prior to par-
ticipation. 
RESULTS
Subjects 
A total of 68 IBS patients (32 males; mean age, 41.4 yr) and 55 
HCs (31 males; 37.4 yr) underwent LBT. The demographic char-
acteristics of the subjects showed no significant difference be-
tween the IBS patients and HCs (Table 1). Thirty five (51%) of 
the 68 IBS patients had IBS-D, 23 (34%) had IBS-C, and 10 (15%) 
had IBS-M. 
LBT results 
The IBS patients had a higher LBT positivity (including hydro-
gen [+] and methane [+]) than HCs (61.8%, 42/68 vs 38.2%, 21/55; 
P = 0.009) (Table 1). LBT positivity for hydrogen was also higher 
in the IBS patients than HCs (55.5%, 35/63 vs 29.1%, 16/55; P =  
0.042). LBT positivity for methane was not different between 
the IBS group and HCs (14.7%, 10/68 vs 9.1%, 5/55; P = 0.344). 
The female patients with IBS had a higher LBT positivity than 
male patients (75.0% vs 47.2%; P = 0.017). LBT positivity was 
not different between the IBS subgroups (60.6%, 21/35 in IBS-
D, 60.9%, 14/23 in IBS-C, and 70.0%, 7/10 in IBS-M). 
Association between hydrogen or methane and IBS 
symptoms 
None of IBS symptoms were noted to be correlated with LBT-
positivity. There were no significant differences in symptom se-
verity scores between the LBT (+) and LBT (-) IBS patients (Fig. 
2A and B). Methane producers were 29.4% (20/68) in the IBS 
patients and 27.3% (15/55) in the HCs, respectively, showing no 
significant difference. Mean symptom severity scores of diarrhea 
and constipation were 7.10 ± 6.71 vs 8.15 ± 6.07 (P = 0.532) and 
6.90 ± 7.39 vs 5.79 ± 6.35 (P = 0.534) in the methane producers 
and non-methane producers, respectively (Table 2). Also, the 
LBT (+) IBS patients for methane did not differ from the LBT (-) 
IBS patients for methane in the symptom severity scores of con-
stipation (7.70 ± 8.27 vs 5.84 ± 6.36, P = 0.419).
Table 1. Characteristics and LBT results in IBS patients and controls
Parameters IBS patients (n = 68) Controls (n = 55) P value 
Age (yr) 41.4 ± 15.6 37.4 ± 11.8 NS 
Gender (Male:Female) 32:36 31:24 NS 
LBT (+) 
  Male:Female 
  Hydrogen (+) 
  Methane (+) 
  Hydrogen and Methane (+) 
42 (61.8%) 
17 (53.1%):24 (66.7%) 
32 (47.1%) 
7 (10.3%) 
3 (4.4%) 
21 (38.2%) 
8 (25.8%):13 (53.2%) 
16 (29.1%) 
5 (9.1%) 
0
0.009
0.017/0.032 
0.042
NS 
IBS, irritable bowel syndrome; LBT, lactulose breath test; NS, not significant.
Fig. 2. (A) The comparison of symptom severity scores in lower gastrointestinal symptoms between IBS patients with LBT (+) and LBT (-) for hydrogen. There were no signifi-
cant differences in the severity scores of IBS symptoms between the groups. (B) The comparison of symptom severity scores in lower gastrointestinal symptoms between IBS 
patients with LBT (+) and LBT (-) for methane. There were no significant differences in the severity scores of IBS symptoms between the groups. 
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Table 2. Comparison of symptom severity between methane producers and non-meth-
ane producers in the IBS patients
Symptoms
Methane producers 
(n = 20) 
Non-methane  
producers (n = 48) 
P value 
Constipation severity 6.90 ± 7.39 5.79 ± 6.35 0.534
Diarrhea severity 7.10 ± 6.71 8.15 ± 6.07 0.532
IBS, irritable bowel syndrome.
Fig. 3. The correlation between symptom severity scores and gas amounts during LBT in the LBT (+) IBS patients. The severity scores of bloating, flatulence and abdominal pain 
were weakly correlated with gas amounts calculated by AUC in the LBT curve. 
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Hydrogen and methane gas amounts measured in the LBT 
and LBT results 
Significantly greater amounts of hydrogen gas were produced in 
the LBT (+) IBS patients than in the LBT (-) IBS patients (5,218 ±  
3,031 vs 2,126 ± 1,879; P < 0.001) and also in the LBT (+) HCs 
(5,218 ± 3,031 vs 3,367 ± 2,142; P = 0.007). Mean amounts of 
hydrogen excretion were not significantly different between the 
total IBS patients and HCs (4,035 ± 3,038 vs 3,154 ± 2,520; P =  
0.087). Also, no difference was found in gas amounts between 
the LBT (+) and LBT (-) HCs (4,431 ± 2,247 vs 3,040 ± 2,147; P =  
0.056). In terms of age, gender, or subtype of IBS, there were no 
significant differences in gas amounts of hydrogen. 
Association between hydrogen and methane gas amounts 
and IBS symptoms 
Symptom severity scores of any GI symptoms were not corre-
lated with hydrogen gas amounts calculated by AUCs of hydro-
gen excretion over time in the LBT. Total gas amounts of hydro-
gen and methane were not associated with none of the IBS sym-
ptoms. Only in the LBT (+) IBS patients, there was a modest cor-
relation between symptom severity scores for bloating (r = 0.364, 
P = 0.018), flatulence (r = 0.314, P = 0.046) and abdominal pain 
(r = 0.324, P = 0.039) and the AUCs of both hydrogen and me-
thane (Fig. 3).
DISCUSSION
Our study shows that hydrogen and methane gas produced by 
intestinal fermentation of lactulose and excreted in the breath 
during LBT are not associated with any IBS symptoms includ-
ing diarrhea and constipation. We also found that gas amounts 
of hydrogen and methane excreted during LBT are not associ-
ated with any GI symptoms of IBS. Therefore, hydrogen or me-
thane gas in the LBT may not be useful in predicting symptom 
severity of IBS and not indicate the subtype of IBS which devel-
op. Additionally, we observed that there is a gender difference 
in LBT results of IBS patients. 
 Hydrogen or methane produced by intestinal fermentation 
of lactulose does not seem to contribute to any IBS symptoms. 
Our data showed that none of the IBS symptoms assessed by 
symptom severity questionnaire were correlated with LBT posi-
tivity for hydrogen or methane. It was previously known that 
hydrogen or methane produced by intestinal bacterial fermen-
tation is inert to the intestine except for its distending effect. 
However, studies have recently reported that methane produc-
tion is associated with IBS-C. The quantity of methane produc-
ed during LBT was described to be proportional to the severity 
of constipation in IBS (12). The effect of methane on the intes-
tine was shown to slow small intestinal transit by augmenting 
small bowel contractility in both animal and human studies (8). 
However, in the present study, constipation severity scores of 
IBS patients with LBT (+) for methane did not differ from those 
with LBT (-) for methane. Furthermore, the proportions of me-
thane producers did not differ between the IBS patients and 
HCs and between IBS-C and IBS-D. Also, symptom severity 
scores for constipation in methane producers were similar to 
those in non-methane producers.
 Regarding methane on constipation in IBS, there is a discrep-
ancy between other studies and ours. A possible explanation is 
that subjects in our study may have reported constipation se-
verity differently from those of other studies; the symptom of 
constipation is variable in expression among patients. Our ques-
tionnaire did not discern the symptom of constipation as such. 
However, in Western studies, investigators usually considered 
the symptom of constipation only in view of stool frequency 
and consistency (10, 12, 15), but our subjects might consider ex-
cessive straining, hard stool, digital evacuation, and incomplete 
evacuation sensation as constipation, even except infrequent 
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defecation. On the other hand, what methane is claimed to be 
associated with constipation by slowing GI transit means that 
methane seems to have a neurotransmitter function on the GI 
tract (8). However, to our knowledge, no evidence exists that 
there is a receptor for methane in the GI tract. Furthermore, 
many studies demonstrating the association between methane 
and constipation have a confounding bias because they did not 
exclude patients with colonic diverticulosis that is a condition 
known to be associated with breath methane excretion (19).
 Taken together, we could speculate that neither hydrogen 
nor methane after lactulose ingestion has any specific effect on 
the development and aggravation of constipation or diarrhea in 
IBS and that LBT positivity for hydrogen or methane does not 
indicate the subtype of IBS.
 The present study results suggest that gas amounts of hydro-
gen and methane excreted during LBT are not associated with 
IBS symptoms. The severity scores of customary IBS symptoms 
assessed by symptom questionnaire were not associated with 
total amounts of hydrogen and methane calculated by AUCs in 
the LBT. These results also indicate that amounts of hydrogen 
or methane produced after lactulose fermentation are not as-
sociated with gas-like symptoms such as bloating in IBS. Bloat-
ing was previously suggested to be due to excessive amounts of 
gas on the intestine. It was also shown that intestinal gas mea-
sured by plain abdominal radiography was greater in IBS pa-
tients than HCs (20). Subgroup analysis in our results revealed 
a weak correlation between symptoms of bloating, flatulence 
and abdominal pain and total gas amounts of hydrogen and 
methane. That means IBS patients with severe degree of cus-
tomary symptoms such as bloating, flatulence or abdominal 
pain may have greater amounts of gas production after lactu-
lose ingestion than those with mild symptoms. However, the 
correlations were very weak, just reached statistical significance, 
and furthermore, observed only in the LBT (+) IBS patients. This 
association confined to the LBT (+) IBS patients may be due to 
our measurements of gas amounts for only 180 min, and not 
until the gas levels have normalized or recovered to the base-
line. LBT (-) subjects may excrete the same amount of gas as 
LBT (+) subjects, only later than 180 min. Furthermore, it was 
reported that 24-hr excretion of hydrogen measured by indirect 
calorimetry was greater in IBS than HC, but no significant dif-
ference in breath hydrogen excretion for 3 hr (21). Taken togeth-
er, our results have a limitation to supporting the idea that hy-
drogen and methane gas amounts produced during LBT have 
an association with gas-like IBS symptoms. 
 The gas amounts excreted during LBT can be explained in a 
way by increased production due to bacterial fermentation of 
lactulose in the small intestine, i.e. SIBO. In diagnosing SIBO, 
various invasive and non-invasive tests such as direct culture 
methods and breath tests using glucose have been used, but 
there have been many problems. In direct culture methods, in-
testinal aspirates are technically limited to the proximal portion 
of the small intestine, and in glucose breath tests, glucose may 
be absorbed in the proximal small intestine instead of being 
fermented by intestinal bacteria. Therefore, both methods may 
underestimate SIBO, i.e. high false negative rate. As for LBT, 
study results are variable according to a diagnostic criterion of 
LBT used (5). In the present study, the 90 min criterion for LBT 
positivity was used because the mean orocecal transit time 
(OCTT) measured by LBT is known to be approximately 90 min, 
although lactulose tend to accelerate OCTT. In the double peak 
criterion, there have been concerns regarding subjectiveness of 
its interpretations and high interobserver variability. The crite-
rion > 20 ppm by 180 min might overestimate the prevalence of 
SIBO by counting subjects fermenting lactulose in their colon. 
 Whether the gas detected in the LBT would have been pro-
duced in the small intestine or in the colon could not be deter-
mined in our study design. It may depend on intestinal transit 
time, particularly OCTT. In subjects with rapid OCTT, lactulose 
are exposed to intestinal bacteria for shorter time periods than 
those with slow OCTT. In subjects with very slow OCTT, lactu-
lose fermentation in the intestine would continue over 3 hr. Also, 
a significant discrepancy was identified between gas produc-
tion in the intestine and gas excretion into the breath (7). That is 
because all the factors such as the diffusivity of a gas, partial 
pressure difference between lumen and blood, and the expo-
sure of the gas to the mucosal surface may affect the excretion 
rate of hydrogen and methane into the breath. Apart from hy-
drogen and methane, metabolism of other intestinal gases in-
cluding N2, O2, and CO2 should be considered. On the other 
hand, a gas infusion study by using nasojejunal tube showed 
that IBS patients with bloating had slower gas transit than con-
trols (22), attributing impaired handling of intestinal gas to blo-
ating (23). Other possible explanations include visceral hyper-
sensitivity to normal amount of intestinal gas (24), abnormally 
weak abdominal musculature intolerable to gaseous distension 
(25), and psychosomatic factors. 
 As for LBT results, gender effect on IBS was also found in the 
present study. Our data showed that the female IBS patients had 
a significantly higher prevalence of LBT positivity than male 
patients. Gender effects on IBS have been also noted not only 
in the prevalence, pathophysiology, and symptomatology of 
IBS but also the response to treatment (26, 27). According to a 
recent report, female IBS patients may have different mucosal 
infiltration by immune cells from male IBS patients (28). It may 
be postulated, considering that intestinal microbiota is respon-
sible for mucosal immune infiltration, that altered intestinal 
microbiota has a potential contribution to gender differences 
in IBS, consistently with our data, although it was not evaluated 
in the study. 
 Several limitations to this study should be considered includ-
ing a limitation of small sample size. First, we enrolled healthy 
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controls with no GI symptoms but general population usually 
has symptoms of bloating and flatulence. Therefore, it might be 
needed to investigate the correlation of LBT results and gas-like 
symptoms in IBS patients and healthy population with bloating 
and flatulence but not meeting the Rome III criteria of IBS, al-
though a study reported that similar gas production caused sym-
ptoms only in IBS patients, not in HC (7). Second, LBT results 
may be affected by a variety of factors including alcohol con-
sumption and smoking history as well as prokinetics. We had to 
manipulate them in order to accurately interpret our data, but 
unfortunately we did not collect these variables. Third, the ques-
tionnaire used was modified from that of previous studies (13, 
14) because only lower GI symptoms of IBS were needed for 
comparing with LBT results. More reliable data could have been 
obtained through a validated questionnaire. The validated ones 
in severity of IBS do not include all of the lower GI symptoms of 
IBS, although they may include HRQOL, psychosocial factors, 
and health-care utilization behavior. Forth, gastric acid barrier 
normally plays one of the protective roles for bacterial overgrow-
th in the GI tract (29). Therefore, acid suppressants including 
proton pump inhibitor (PPI) may predispose subjects to SIBO 
(30) and gas amount in the LBT could be altered in PPI users. 
Therefore, our study should have excluded PPI users at enroll-
ment. However, the inclusion of PPI users in our study may not 
have affected results, considering a recent report that 46.2% of 
106 patients taking PPIs were positive for SIBO, which is not 
significantly different from 56.3% positives among non-PPI us-
ers (31). On the other hand, this study also reported that meth-
ane detection was lower in PPI users than non-PPI users, which 
suggests to pay attention to interpretation of our data. 
 In conclusion, methane and hydrogen on the LBT is not as-
sociated with specific symptoms in IBS patients. Furthermore, 
hydrogen and methane gas amounts calculated by AUC in the 
LBT are not associated with IBS symptoms. Our results indicate 
that hydrogen and methane in the LBT are not useful for pre-
dicting customary IBS symptoms and the form of IBS which 
develop. In order to understand symptomatology and patho-
physiology of IBS, further Studies are needed for investigating 
other gases and their metabolism as well as hydrogen and me-
thane.
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